For: | Muñoz-Guglielmetti D, Sanchez-Lorente D, Reyes R, Martinez D, Lucena C, Boada M, Paredes P, Parera-Roig M, Vollmer I, Mases J, Martin-Deleon R, Castillo S, Benegas M, Muñoz S, Mayoral M, Cases C, Mollà M, Casas F. Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations. World J Clin Oncol 2021; 12(11): 1047-1063 [PMID: 34909399 DOI: 10.5306/wjco.v12.i11.1047] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v12/i11/1047.htm |
Number | Citing Articles |
1 |
Sungjin Kim, Jeonghyo Lee, Jin-Haeng Chung. Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non–Small Cell Lung Cancer with Neoadjuvant Therapy. Cancer Research and Treatment 2025; 57(2): 401 doi: 10.4143/crt.2024.670
|
2 |
Hengyu Zhai, Wenhai Li, Kun Jiang, Yanan Zhi, Zhao Yang. Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study. Cancer Management and Research 2022; : 515 doi: 10.2147/CMAR.S344343
|